Chartwell Investment Partners LLC acquired a new stake in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 184,337 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,403,000. Chartwell Investment Partners LLC owned about 0.57% of Collegium Pharmaceutical as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Manchester Capital Management LLC bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at about $348,000. Teton Advisors Inc. boosted its holdings in shares of Collegium Pharmaceutical by 18.5% during the 4th quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock valued at $591,000 after purchasing an additional 5,000 shares during the last quarter. Monarch Partners Asset Management LLC bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at about $264,000. Granite Investment Partners LLC boosted its holdings in shares of Collegium Pharmaceutical by 34.1% during the 4th quarter. Granite Investment Partners LLC now owns 69,920 shares of the specialty pharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 17,784 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of Collegium Pharmaceutical by 489.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 332,587 shares of the specialty pharmaceutical company’s stock valued at $6,140,000 after purchasing an additional 276,123 shares during the last quarter. 87.60% of the stock is owned by institutional investors and hedge funds.
Shares of Collegium Pharmaceutical Inc (NASDAQ COLL) traded down $0.28 during midday trading on Wednesday, hitting $27.31. 766,400 shares of the stock traded hands, compared to its average volume of 634,005. The stock has a market cap of $889.28 and a PE ratio of -11.01. Collegium Pharmaceutical Inc has a 52-week low of $7.37 and a 52-week high of $29.90.
COLL has been the subject of several research reports. Piper Jaffray Companies set a $33.00 price objective on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, January 23rd. BidaskClub downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Needham & Company LLC upped their target price on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group upped their target price on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $29.17.
In related news, insider Alison B. Fleming sold 6,928 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total value of $132,116.96. Following the sale, the insider now directly owns 32,651 shares of the company’s stock, valued at approximately $622,654.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of the stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $22.50, for a total transaction of $450,000.00. Following the completion of the sale, the chairman now directly owns 538,987 shares in the company, valued at $12,127,207.50. The disclosure for this sale can be found here. Insiders sold a total of 46,928 shares of company stock worth $1,082,317 over the last three months. 25.76% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Chartwell Investment Partners LLC Buys Shares of 184,337 Collegium Pharmaceutical Inc (COLL)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/03/14/chartwell-investment-partners-llc-acquires-shares-of-184337-collegium-pharmaceutical-inc-coll.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.